Clinical Trials Logo

Bowen's Disease clinical trials

View clinical trials related to Bowen's Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05402046 Recruiting - Melanoma (Skin) Clinical Trials

Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms

CAMELLIA
Start date: April 23, 2022
Phase: N/A
Study type: Interventional

A Multicenter, Prospective, Low-interventional Clinical Study Evaluating on mobile application validation ("ProRodinki") in assessing the risk of skin malignant neoplasms

NCT ID: NCT03909646 Recruiting - Bowen's Disease Clinical Trials

Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease

BOWTIE
Start date: May 27, 2019
Phase: Phase 4
Study type: Interventional

There is limited quality research on the effectiveness of treatments in Bowen's disease (BD). Patient and lesion characteristics, patient preferences and costs should be considered when choosing therapy. Surgical excision (SE), photodynamic therapy (PDT) and 5-fluorouracil (5FU) are mentioned as treatment options in guidelines. However no clear and evidence based recommendations are made in terms of effectiveness. Objective: The aim of this study is 1) to evaluate the (cost)effectiveness of 5FU and PDT compared to SE in BD and 2) to compare the effectiveness of 5FU with that of PDT. With a better understanding of the (cost)effectiveness of alternative treatment options, the investigators will supply the necessary evidence for national and international guidelines, to achieve more uniformity in treatment of BD. Study design: Randomized controlled non-inferiority multicenter trial. Study population: Patients ≥18 years, with a histological proven primary lesion of Bowen's disease, visiting Maastricht University Medical Centre, Catharina hospital Eindhoven, VieCuri MC Venlo or Zuyderland Medical Centre Heerlen. Intervention: One group undergoes SE with a 5mm safety margin followed by routine histological examination. The other group receives PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval. The third group receives 5FU cream, which has to be applied by the patient twice daily for 4 weeks. Main study parameters/endpoints: The primary outcome is the proportion of patients with sustained clearance at 12 months post-treatment. Secondary outcomes are proportion of patients with clearance at 3 months, 3-year and 5-year probability of sustained clearance, cost-effectiveness, patient satisfaction, patient preferences, compliance, side effects and cosmetic outcome. Post-treatment, patients will be asked to answer a short questionnaire regarding side effects, experience with the treatment and satisfaction.

NCT ID: NCT03641079 Recruiting - Clinical trials for Keratotic Nodular Size

Identification of Compound From Brinjal Peel Extract in the Treatment of Palmar Arsenical Keratosis and Bowen's Disease

Start date: September 16, 2017
Phase: Phase 2
Study type: Interventional

Arsenicosis is a major health problem in Bangladesh. Long term exposure of arsenic causes keratosis of palm which reduce working capacity of patient. It also causes invasive skin lesions like Bowen's disease which has a risk to develop squamous cell carcinoma. Brinjal peel is well known for its antioxidant and anticancer properties. So this study will be conducted to identify the compound from brinjal peel extract and to see its outcome on keratosis and Bowen's disease.

NCT ID: NCT02759900 Recruiting - Actinic Keratosis Clinical Trials

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

Start date: January 2016
Phase: N/A
Study type: Interventional

This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders

NCT ID: NCT00166946 Recruiting - Bowen Disease Clinical Trials

Effects of Arsenic on Keratinocytes in a Skin Equivalent Model

Start date: June 2005
Phase: N/A
Study type: Interventional

We popose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen’s disease.